163 related articles for article (PubMed ID: 28697993)
41. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR
Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410
[TBL] [Abstract][Full Text] [Related]
42. Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation.
Choi SH; Park S; Oh CJ; Leem J; Park KG; Lee IK
Vascul Pharmacol; 2015 Oct; 73():11-9. PubMed ID: 26187356
[TBL] [Abstract][Full Text] [Related]
43. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
[TBL] [Abstract][Full Text] [Related]
44. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
Bae EJ
Arch Pharm Res; 2016 Aug; 39(8):1114-28. PubMed ID: 27502601
[TBL] [Abstract][Full Text] [Related]
45. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
[TBL] [Abstract][Full Text] [Related]
46. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
47. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
Uchii M; Kimoto N; Sakai M; Kitayama T; Kunori S
Eur J Pharmacol; 2016 Jul; 783():56-63. PubMed ID: 27063445
[TBL] [Abstract][Full Text] [Related]
48. Susceptibility of milk protein-derived peptides to dipeptidyl peptidase IV (DPP-IV) hydrolysis.
Nongonierma AB; FitzGerald RJ
Food Chem; 2014 Feb; 145():845-52. PubMed ID: 24128555
[TBL] [Abstract][Full Text] [Related]
49. Features of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides from dietary proteins.
Nongonierma AB; FitzGerald RJ
J Food Biochem; 2019 Jan; 43(1):e12451. PubMed ID: 31353485
[TBL] [Abstract][Full Text] [Related]
50. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.
Kröller-Schön S; Knorr M; Hausding M; Oelze M; Schuff A; Schell R; Sudowe S; Scholz A; Daub S; Karbach S; Kossmann S; Gori T; Wenzel P; Schulz E; Grabbe S; Klein T; Münzel T; Daiber A
Cardiovasc Res; 2012 Oct; 96(1):140-9. PubMed ID: 22843705
[TBL] [Abstract][Full Text] [Related]
51. Dipeptidyl peptidase IV inhibitory peptides generated in Spanish dry-cured ham.
Gallego M; Aristoy MC; Toldrá F
Meat Sci; 2014 Feb; 96(2 Pt A):757-61. PubMed ID: 24200567
[TBL] [Abstract][Full Text] [Related]
52. The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure.
Hirose M; Takano H; Hasegawa H; Tadokoro H; Hashimoto N; Takemura G; Kobayashi Y
J Pharmacol Sci; 2017 Dec; 135(4):164-173. PubMed ID: 29249634
[TBL] [Abstract][Full Text] [Related]
53. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
54. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.
Omar B; Ahrén B
Diabetes; 2014 Jul; 63(7):2196-202. PubMed ID: 24962916
[TBL] [Abstract][Full Text] [Related]
55. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
[TBL] [Abstract][Full Text] [Related]
56. Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.
Ahmed HA; May DW; Fagan SC; Segar L
Pharmacotherapy; 2015 Mar; 35(3):277-97. PubMed ID: 25754657
[TBL] [Abstract][Full Text] [Related]
57. Identification of Potential Dipeptidyl Peptidase (DPP)-IV Inhibitors among
Yang Y; Shi CY; Xie J; Dai JH; He SL; Tian Y
Molecules; 2020 Jan; 25(1):. PubMed ID: 31906524
[No Abstract] [Full Text] [Related]
58. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
59. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
[TBL] [Abstract][Full Text] [Related]
60. The effects of DPP-4 inhibitor on hypoxia-induced apoptosis in human umbilical vein endothelial cells.
Nagamine A; Hasegawa H; Hashimoto N; Yamada-Inagawa T; Hirose M; Kobara Y; Tadokoro H; Kobayashi Y; Takano H
J Pharmacol Sci; 2017 Jan; 133(1):42-48. PubMed ID: 28081947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
